Zafgen, Inc. Strengthens Executive Leadership Team with Appointment of Industry Veteran Priya Singhal as Head of Research and Development
March 04, 2019 07:00 ET
|
Zafgen, Inc.
BOSTON, March 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen Announces Positive Results for Second Cohort of Phase 2 Clinical Trial of ZGN-1061
January 17, 2019 07:00 ET
|
Zafgen, Inc.
Data for the 1.8 mg dose demonstrated meaningfully greater efficacy than the 0.9 mg dose Cohort 2 data showed statistically and clinically significant 1.1% reduction of A1C at the 1.8 mg dose...
Zafgen Provides Update on Investigational New Drug Application for ZGN-1061
November 26, 2018 07:00 ET
|
Zafgen, Inc.
BOSTON, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen to Present at the 30th Annual Piper Jaffray Healthcare Conference
November 21, 2018 16:05 ET
|
Zafgen, Inc.
BOSTON, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen Reports Third Quarter 2018 Operating and Financial Results
November 07, 2018 16:05 ET
|
Zafgen, Inc.
ZGN-1061 1.8 mg cohort for the Phase 2 proof-of-concept trial now fully enrolled; on track for topline results early 2019 ZGN-1258 nonclinical safety and efficacy data sets presented at Foundation...
Zafgen to Present at the Stifel 2018 Healthcare Conference
November 06, 2018 16:05 ET
|
Zafgen, Inc.
BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen to Host Conference Call to Discuss Third Quarter 2018 Financial Results
November 01, 2018 08:00 ET
|
Zafgen, Inc.
BOSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen to Present Data from Multiple Nonclinical, IND-Enabling Studies of ZGN-1258 at the 2018 Foundation for Prader-Willi Research Family Conference
October 04, 2018 07:00 ET
|
Zafgen, Inc.
Nonclinical data for ZGN-1258 reproduce efficacy seen in first generation candidate for PWS Data show highly improved safety profile Company also presenting study design of PATH for PWS natural...
Zafgen to Present at the Wedbush PacGrow Healthcare Conference
August 08, 2018 16:05 ET
|
Zafgen, Inc.
BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen Reports Second Quarter 2018 Operating and Financial Results
August 07, 2018 16:05 ET
|
Zafgen, Inc.
Phase 1 clinical trial for ZGN-1258 for Prader-Willi syndrome (PWS) expected to begin in the fourth quarter 2018 Multiple ZGN-1258 nonclinical studies accepted for presentation at upcoming Foundation...